Pharmacological intervention based on fecal calprotectin levels in patients with ulcerative colitis at high risk of a relapse: A prospective, randomized, controlled study.

BÜHLMANN fCAL® ELISA Citation

Lasson, A. et al., 2014, Pharmacological intervention based on fecal calprotectin levels in patients with ulcerative colitis at high risk of relapse: A prospective, randomized, controlled study, United European Gastroenterology Journal.  PMID: 25653861 DOI: 10.1177/2050640614560785

Highlight from this Publication

“In patients with UC, FC-guided dosing of the patient’s 5-ASA agent showed significantly lower relapse rates than for patients in the control group.”

BÜHLMANN fCAL® ELISA is FDA 510(k) cleared For in vitro Diagnostic Use.

Health Canada License: 80726